

Combined Sections Meeting
 February 19, 2016
 Regine L. Souverain, PT, DPT, C/NDT, PCS
 Memorial Sloan Kettering Cancer Center

DEVELOPMENTAL DELAY IN THE INFANT CANCER PATIENT AND THE ROLE OF PHYSICAL THERAPY

Disclosure

This presenter has no conflict of interest to report regarding any commercial product/manufacture that may be referenced during this presentation.

Objectives

- To discuss the cancers most often seen during infancy.
- To define developmental delay and how it is determined.
- To understand the causes of developmental delay in infants with cancer.
- To explore the role of physical therapy in the management of developmental delay in this population.

Statistics ^{1,2}

- Cancer in childhood is RARE
 - 1% of all cancer diagnoses
 - 15,780 estimated cases in 2014
- Occurs less likely during infancy – the first year of life
 - 23:100,000 infants diagnosed annually

Infant Cancers ^{3,4}

- Different epidemiological, clinical and genetic characteristics than cancers seen in older children
- Diagnostic challenge to identify malignancy
- Treatment decisions must take into account
 - Inherent vulnerability of infants
 - Small size
 - Potential toxicity

Infant Cancers

- Neuroblastoma
- Leukemia
- Brain tumors
- Retinoblastoma
- Wilms tumor

Neuroblastoma ^{3,5,6}


- Neuroblastoma is a cancer of neuroblasts in the sympathetic nervous system
- Represents 6% of all pediatric cancers
 - 700 new cases diagnosed annually
 - 1/3 of all malignancies seen in infants
- Average age of diagnosis is ~1-2 years of age
 - 90% of cases before age 5

Neuroblastoma ^{3,5,6}

- Risk factors
 - Age, genetic predisposition
- Common locations
 - Adrenal gland
 - Abdominal sympathetic nerve ganglia
 - Spinal sympathetic nerve ganglia (chest, neck, pelvis)

Neuroblastoma ^{3,5,6}


- Symptoms include:
 - Lump/swelling
 - Abdomen
 - Neck
 - Lymph nodes
 - Bone pain
 - Weakness
 - Blueberry muffin sign
 - Opsoclonus-myoclonus



www.cancer.gov

Neuroblastoma ^{3,5,6}

- Methods of diagnosis
 - Imaging tests
 - Ultrasound
 - CT scan
 - MIBG scan
 - PET scan
 - Laboratory tests
 - Blood
 - Urine catecholamine
- Biopsy
 - Surgical
 - Bone marrow



jnm.snmjournals.org

Neuroblastoma ⁵

Tumor Staging

Stage 1	Stage 2A	Stage 2B	Stage 3	Stage 4	*Stage 4S
• No spread, unilateral tumor involvement, complete surgical removal	• No spread, unilateral tumor involvement, incomplete surgical removal	• Unilateral tumor involvement, complete or incomplete surgical removal, lymph node involvement	• Unilateral or bilateral tumor involvement, complete or incomplete surgical removal, midline tumor involvement,	• Metastatic disease	• <1 year old

Neuroblastoma ^{5,8}

- Treatment includes:
 - Surgery
 - Tumor resection
 - Chemotherapy
 - Carboplatin
 - Cisplatin
 - Cyclophosphamide
 - Doxorubicin
 - Etoposide
 - Ifosfamide
 - Topotecan
 - Radiation
 - MIBG
 - Immunotherapy
 - Stem cell transplant

Neuroblastoma ⁵

- Prognosis

Risk Group	5-Year Survival Rate
Low Risk	95%
Intermediate Risk	90-95%
High Risk	40-50%


Leukemia ^{3,9,10}

- Leukemia is a cancer of blood-forming cells
 - Most common cancer seen in children
 - Represents 26% of all pediatric cancers
 - Second most common cancer in infants
- Risk factors
 - Genetic predisposition, radiation, chemotherapy

Leukemia ^{3,9,10}

- Types
 - Acute lymphoblastic leukemia (ALL)
 - Acute myelogenous leukemia (AML)
 - Hybrid/mixed leukemia
 - Juvenile myelogenous leukemia (JMML)
 - Chronic forms of leukemia are uncommon in childhood

Leukemia ³



Leukemia ^{3,9,10}

- Symptoms
 - Cutaneous infiltration
 - Fatigue
 - Pallor
 - Easy bruising
 - Weakness
 - Infections



www.visualdx.com

Leukemia ^{9,10,11}

- Methods of diagnosis
 - Laboratory tests
 - Blood tests (CBC)
 - Biopsy
 - Bone marrow aspiration/biopsy
 - Lumbar puncture



www.fotosearch.com

Leukemia ^{9,11}

ALL
Classification

- Based on immunotype
 - B-cell ALL (80-85%)
 - Early precursor B-cell ALL
 - Common ALL
 - Pre-B ALL
 - Mature B-cell ALL
 - T-cell ALL (15-20%)

Leukemia ^{9,11}

AML
Classification

- Based on morphology
 - M0, M1, M2, M3, M4, M5
 - Starts in immature forms of WBC
 - M6
 - Starts in immature forms of red blood cells
 - M7
 - Starts in immature forms of cells that make platelets

Leukemia ^{9,12}

- Treatment
 - Chemotherapy
 - Vincristine
 - Daunorubicin
 - Doxorubicin
 - Cytarabine
 - L-asparaginase
 - Etoposide
 - Methotrexate
 - Cyclophosphamide
 - Prednisone
 - Dexamethasone
 - Stem cell transplant
 - High risk disease
 - Relapsed disease
 - Radiation
 - CNS involvement
 - Testicular involvement
 - Pre-SCT

Leukemia ⁹

- Prognosis

Leukemia Type	5-Year Survival Rates
ALL	85%
AML	60-70%
JMML	50%

Brain Tumors ^{3,13,14}

- Brain tumors are abnormal growths in the brain (benign and malignant)
 - Second most common cancer seen in children
 - Most common solid tumor seen in children
 - Represents 19% of all pediatric cancers
 - Third most common cancer seen in infants

Brain Tumors ¹⁴

Histology Classification - WHO

Gliomas

- Astrocytomas
- Oligodendrocytomas
- Ependymomas

Primitive neuroectodermal tumors

- Medulloblastomas
- PNET
- Atypical teratoid rhabdoid tumors

Cranial nerves

Meninges

Brain Tumors 14

Location Classification - ICC

Supratentorial

- Four lobes
- Cerebrum
- Ventricle

Infratentorial

- Cerebellum
- Brainstem


Gland

- Pituitary
- Pineal

Cranial nerves

Meninges

Brain Tumors



www.acco.org

Brain Tumors 3,13,14

General Symptoms

- Macrocephaly
- Irritability
- Nausea/Vomiting
- Headache
- Seizures
- Motor weakness

Site Specific Symptoms

- Cerebrum
 - Hemiparesis
 - Sensory loss
 - Speech and memory disturbances
- Posterior fossa
 - Abnormal gait
 - Incoordination
- Brainstem
 - Cranial nerve deficits


Brain Tumors 13,14

- Risk factors
 - Radiation, genetic predisposition
 - Neurofibromatosis (1, 2), Li-Fraumeni syndrome

Brain Tumors 13

• Methods of diagnosis

- Imaging Tests
 - MRI
 - CT scan
- Biopsy
 - Stereotactic
 - Craniotomy
- Lumbar puncture



www.chrichmond.org

Brain Tumors 13,16

- Treatment includes:
 - Surgery
 - Craniotomy
 - Shunt placement
 - Ventriculoperitoneal (VP) shunt
 - External ventricular drain (EVD)
 - Ommaya reservoir
 - Chemotherapy
 - Carboplatin
 - Carmustine
 - Cisplatin
 - Cyclophosphamide
 - Etoposide
 - Lomustine
 - Methotrexate
 - Temozolomide
 - Thiotepa
 - Vincristine
 - Radiation

Brain Tumors ¹³

- Prognosis

Tumor Types	5-Year Survival Rates
Pilocytic Astrocytoma	~95%
Fibrillary Astrocytoma	~80-85%
Anaplastic Astrocytoma	~30%
Glioblastoma	~20%
Oligodendroglioma	~90-95%
Ependymoma/Anaplastic Ependymoma	~75%
PNETs (Medulloblastoma, Pineoblastoma)	~60-65%

Retinoblastoma ^{3,17,18}

- Retinoblastoma is a cancer of the eye, starts in the retina
 - Most common eye cancer seen in children
 - Represents 2% of all pediatric cancers
 - 200-300 cases diagnosed annually
 - 11% of cancers diagnosed in the 1st year of life
- Average age of diagnosis is 2

Retinoblastoma ^{17,18}

- Risk factors
 - Age, genetic predisposition
 - RB1 gene

Retinoblastoma ^{17,18}

- Types of retinoblastoma
 - Congenital (hereditary)
 - Sporadic
- Can be unilateral, bilateral or trilateral

Retinoblastoma ^{17,18}

- Symptoms include
 - Leukocoria
 - Strabismus
 - Pain
 - Decreased vision



webevs.opth.u.iowa.edu

Retinoblastoma ^{3,17,17}

- Methods of diagnosis
 - Imaging tests
 - Ultrasound
 - MRI
 - Ophthalmologic exam

Retinoblastoma ¹⁷

Tumor Staging

Group A	Group B	Group C	Group D	Group E
• 3 mm or less, confined to the retina	• >3 mm or small and close to optic disc or fovea	• Well defined, small subretinal or vitreous seeding	• Large or poorly defined, widespread subretinal or vitreous seeding, possible retinal detachment	• Large, extends forward, bleeding or causing glaucoma

Retinoblastoma ^{3,17,18}

- Treatment includes:
 - Surgery
 - Enucleation
 - Radiation
 - External beam
 - Brachytherapy
 - Cryotherapy
 - Thermotherapy
 - Photocoagulation
 - Stem cell transplant
- Chemotherapy
 - Carboplatin
 - Cisplatin
 - Cyclophosphamide
 - Doxorubicin
 - Etoposide
 - Vincristine
 - Topotecan

Retinoblastoma ¹⁷

- Prognosis

Type	Survival Rate
Overall	94% (5-year)
Metastatic Disease	50%
Trilateral	44% (pineal) 57% (non-pineal)

Wilms Tumor ^{3,19}

- Wilms tumor is a primary cancer of the kidneys
 - Most common kidney cancer in children
 - Represents 5% of all pediatric cancers
 - 500 cases diagnosed annually
- Average age of diagnosis is ~3-4 years of age
- Risk factors
 - Age, gender, race, genetic predisposition

Wilms Tumor ^{3,19,20}


- Types of Wilms tumor
 - Favorable histology
 - Unfavorable histology
- Can be unilateral or bilateral
- Symptoms
 - Abdominal mass/swelling, fever, decreased appetite, nausea



medicalpedia.org

Wilms Tumor ^{19,20}

- Methods of diagnosis
 - Imaging tests
 - Ultrasound
 - CT scan
 - MRI
 - Biopsy



med.brown.edu

Wilms Tumor ^{19,21}

Tumor Staging

Stage I (40-45%)	Stage II (20%)	Stage III (20-25%)	Stage IV (10%)	Stage V (5%)
<ul style="list-style-type: none"> • Unilateral, complete surgical removal, intact renal capsule 	<ul style="list-style-type: none"> • Tumor extension into fatty tissue or blood vessels, complete surgical removal, no lymph node involvement 	<ul style="list-style-type: none"> • Incomplete surgical removal, limited to the abdomen 	<ul style="list-style-type: none"> • Metastatic spread beyond the kidney 	<ul style="list-style-type: none"> • Bilateral kidney involvement at diagnosis

Wilms Tumor ^{19,21}

- Treatment
 - Surgery
 - Radical nephrectomy
 - Partial nephrectomy
 - Radiation
- Chemotherapy
 - Actinomycin D
 - Vincristine
 - Doxorubicin
 - Cyclophosphamide
 - Etoposide
 - Irinotecan
 - Carboplatin

Wilms Tumor ^{19,21}

- Prognosis

Tumor Stage	Favorable Histology	Unfavorable Histology
Stage I	99%	83%
Stage II	98%	81%
Stage III	94%	72%
Stage IV	86%	38%
Stage V	87%	55%

Severe Combined Immunodeficiency (SCID) ^{22,23}

- Primary immunodeficiency
 - Heterogeneous group of disorders which arise from a disturbance in the development and function of immunity
 - T cells
 - B cells
- “Severe” - lead to early death from significant infections

Severe Combined Immunodeficiency (SCID) ²³

- Statistics
 - 1:50,000-100,000 live births

Severe Combined Immunodeficiency (SCID) ^{22,23,23}

Types

- X-linked SCID
- Adenosine deaminase (ADA) deficiency
- Artemis, recombinaase activating gene (RAG)
 - RAG 1
 - RAG 2
- Janus kinase (JAK3) deficiency
- Deficiencies in CD3 complex components
- Reticular dysgenesis

Severe Combined Immunodeficiency (SCID) ^{22,23}

- Symptoms
 - Recurrent infections
- Diagnosis
 - Newborn screen
- Treatment
 - Stem cell transplant
 - Enzyme replacement therapy

Developmental Delay

Developmental Delay

- Defined as “a significant delay in the process of development”
- Can occur as a result of various causes
 - Pre-natal
 - Maternal infection
 - Genetic syndromes
 - Peri-natal
 - Difficult childbirth
 - Post-natal
 - Brain injury

Developmental Delay ²⁵

- Can be seen across several domains/areas of development
 - Physical
 - Gross motor
 - Fine motor
 - Feeding
 - Cognitive
 - Speech
 - Learning
 - Communication


Developmental Areas ²⁵

- | | |
|------------------|---|
| Gross Motor | • Use of large muscles |
| Fine Motor | • Use of small muscles |
| Speech/Language | • Producing and understanding speech |
| Cognitive | • Learning and problem solving |
| Social/Emotional | • Interaction with others, self-control |

Developmental Milestones

- A skill that a child achieves within a specific time frame
- Occurs in a sequential fashion
- Can be used as an indication of potential delay

Developmental Milestones



Standardized Assessments

- Quantifies amount of delay
- Provides specific information for clinician and parent
- Justifies need for services
- Tracks progress over time

Standardized Assessments

- Alberta Infant Motor Scales (AIMS)
- Peabody Developmental Motor Scale (PDMS)
- Developmental Assessment of Young Children (DAYC)

AIMS

- Norm-referenced test
- Birth to 18 months
- Purpose
 - Identify children with delayed motor development
 - Evaluate motor development/maturation over time

AIMS

Areas of Assessment

- Prone
- Supine
- Sitting
- Standing

PDMS

- Norm-referenced test
- Birth to 5 years old
- Purpose
 - Qualitative and quantitative assessment of fine and gross motor development
 - Recommends activities to address problems

PDMS

Subtests

- Reflexes
- Stationary
- Locomotion
- Object Manipulation
- Grasping
- Visual-Motor

DAYC

- Norm-referenced test
- Birth to 5 years
- Purpose
 - Identify normal and delayed development
 - Determine specific strengths/weaknesses
 - Document progress related to intervention

DAYC

Subtests

- Cognitive
- Communication
- Social-Emotional
- Physical Development
- Adaptive Behavior

Developmental Delay in Infant Cancers

Causes of Developmental Delay in Infant Cancers

- Treatment side effects
 - Chemotherapy
 - Myelosuppression → decreased energy/activity tolerance, infection
 - Mucositis → impaired oral feeding, impaired weight gain
 - Radiation
 - Fatigue → decreased energy/activity tolerance
 - Surgery
 - Pain → faulty posturing/alignment, impaired reaching/ROM

Causes of Developmental Delay in Infant Cancers

- Line placement
 - Can impede “tummy time” and tolerance of prone positioning, limited UE reaching
 - Central lines
 - Mediport
 - Broviac
 - Feeding tubes
 - PEG/PEG



krissygallagher.worldpress.com www.preemiebabies101.com

Causes of Developmental Delay in Infant Cancers

- Prolonged positioning
 - Impaired alignment
 - Decreased ROM
- Environment
 - Home vs. hospital
 - Limited consistency
 - Impaired sleep/wake cycle
 - Isolation (masks, gloves, gowns)
 - Decreased interaction with peers/social interaction

Role of Physical Therapy

PT Intervention

- Assessment
 - Strength/ROM
 - Muscle tone
 - Alignment
 - Neurological function
 - Resting position
 - Balance
 - Transitions
 - Skill acquisition
 - Play/mobility in supine, prone, sitting, standing

PT Intervention

- Goals
 - Based on current and expected skill level
 - Consider various positions and transitions
 - May require increased time to achieve
 - Involve parents and caregivers


PT Intervention

- Frequency
 - Things to consider
 - Amount of delay
 - Activity tolerance
 - Parental wishes/input
 - Medical treatment needs

PT Intervention

- PT Treatment
 - Strengthening
 - Tolerance of positioning (tummy time, sitting, standing)
 - Balance
 - Gross motor skill acquisition
 - Transitions
 - Ambulation
 - Sensory integration
 - Endurance/cardiopulmonary

Intervention – Team Approach



Intervention – Team Approach



Case Studies

Case Study

- Diagnosed via newborn screen with SCID
- Treatment
 - SCT x 2
- Complications
 - Transplant failure
 - Multiple infections (respiratory, bacterial/viral)
 - Hemolytic anemia requiring multiple transfusions
 - Impaired feeding

Case Study

- Multiple hospital admissions
 - Extended time
 - Consistently on isolation
 - Transfers to PICU for escalated care
- Rehab history
 - Initially evaluated at 3 months
 - Currently receives PT 3x/wk at 2 years old
 - Inpatient, outpatient, early intervention

Case Study

- A few developmental milestones...
 - Head lag, cervical rotation and tilt, hands fistled at 3 months
 - Rolled at 5-6 months
 - Sat independently at 7 months
 - Maintained quadruped at 9 months
 - Showed regression of skills at 11 months
 - Took first independent steps at almost 2 years old

Literature Review 26

“Physical Functioning in Pediatric Survivors of Childhood Posterior Fossa Brain Tumors” – Piscione, et al

- Cross-sectional assessment of physical functioning using the Bruininks-Osteretsky Test of Motor Performance (BOT-2)
 - Statistically significant differences noted in survivors observed in bilateral coordination, balance and running speed/agility

Literature Review 27

“Motor Development of Infants with Positional Plagiocephaly” – Kennedy, et al

- Compared the motor development of infants with positional plagiocephaly (PP) and matched peers without using the AIMS and PDMS
 - Young infants placed predominately in the supine position tend to posture their heads preferentially to one side
 - Infants with PP who spent less awake time in prone had lower motor scores

References

1. American Cancer Society. Special Section: Cancer in Children & Adolescents. Available at <http://www.cancer.org/acs/groups/content/@research/document/cpe-041787.pdf>. Accessibility verified 1/3/16
2. St. Baldrick's Foundation. Babies and Cancer. Available at <http://www.stbaldricks.org/blog/post/babies-and-cancer-at-stbaldricks-072-00c700e0e0d0c0e0>. Availability verified 1/3/16
3. Lin, Y. (2003) Early Recognition of Infant Malignancy: The Five Most Common Infant Cancers. *Neonatal Network*, 22, 11-19
4. Orbach, et al. (2013). Neonatal cancer. *Lancet Oncology*, 14, 609-620
5. American Cancer Society. Neuroblastoma. Available at <http://www.cancer.org/cancer/neuroblastoma/detailedguide/index>. Availability verified 1/3/16
6. Up to Date. Clinical presentation, diagnosis, and staging evaluation of neuroblastoma. Available at http://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-evaluation-of-neuroblastoma?source=search_result&search=neuroblastoma&selectedTitle=26,71150. Availability verified 1/3/16
7. Up to Date. Epidemiology, pathogenesis and pathology of neuroblastoma. Available at http://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-neuroblastoma?source=search_result&search=neuroblastoma&selectedTitle=26,71150. Availability verified 1/3/16
8. Up to Date. Treatment and prognosis of neuroblastoma. Available at http://www.uptodate.com/contents/treatment-and-prognosis-of-neuroblastoma?source=search_result&search=neuroblastoma&selectedTitle=26,71150. Availability verified 1/3/16
9. American Cancer Society. Childhood Leukemia. Available at <http://www.cancer.org/cancer/leukemia-in-children/detailedguide/index>. Availability verified 1/3/16
10. Up to Date. Overview of the presentation and diagnosis of acute lymphoblastic leukemia in children and adolescents. Available at http://www.uptodate.com/contents/overview-of-the-presentation-and-diagnosis-of-acute-lymphoblastic-leukemia-in-children-and-adolescents?source=search_result&search=acute-lymphoblastic-leukemia&selectedTitle=16,71150. Availability verified 1/3/16

References

11. Up to Date. Risk group stratification and prognosis for acute lymphoblastic leukemia in children and adolescents. Available at http://www.uptodate.com/contents/risk-group-stratification-and-prognosis-for-acute-lymphoblastic-leukemia-in-children-and-adolescents?source=search_result&search=acute-lymphoblastic-leukemia&selectedTitle=76,71150. Availability verified 1/3/16
12. Up to Date. Overview of the treatment of acute lymphoblastic leukemia in children and adolescents. Available at http://www.uptodate.com/contents/overview-of-the-treatment-of-acute-lymphoblastic-leukemia-in-children-and-adolescents?source=search_result&search=acute-lymphoblastic-leukemia&selectedTitle=26,71150. Availability verified 1/3/16
13. American Cancer Society. Brain and Spinal Cord Tumors in Children. Available at <http://www.cancer.org/cancer/brain-and-spinal-cord-tumors-in-children/detailedguide/index>. Availability verified 1/3/16
14. Up to Date. Epidemiology of central nervous system tumors in children. Available at http://www.uptodate.com/contents/epidemiology-of-central-nervous-system-tumors-in-children?source=search_result&search=central-nervous-system-tumors-in-children&selectedTitle=35,71150. Availability verified 1/3/16
15. Up to Date. Clinical manifestations and diagnosis of central nervous system tumors in children. Available at http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-central-nervous-system-tumors-in-children?source=search_result&search=central-nervous-system-tumors-in-children&selectedTitle=16,71150. Availability verified 1/3/16
16. Up to Date. Overview of the management of central nervous tumors in children. Available at http://www.uptodate.com/contents/overview-of-the-management-of-central-nervous-system-tumors-in-children?source=search_result&search=central-nervous-system-tumors-in-children&selectedTitle=26,71150. Availability verified 1/3/16
17. American Cancer Society. Neuroblastoma. Available at <http://www.cancer.org/cancer/neuroblastoma/detailedguide/index>. Availability verified 1/3/16
18. Up to Date. Overview of neuroblastoma. Available at http://www.uptodate.com/contents/overview-of-neuroblastoma?source=search_result&search=neuroblastoma&selectedTitle=16,71150. Availability verified 1/3/16
19. American Cancer Society. Wilms Tumor. Available at <http://www.cancer.org/cancer/wilms-tumor/detailedguide/index>. Availability verified 1/3/16
20. Up to Date. Presentation, diagnosis, and staging of Wilms tumor. Available at http://www.uptodate.com/contents/presentation-diagnosis-and-staging-of-wilms-tumor?source=search_result&search=wilms-tumor&selectedTitle=16,71150. Availability verified 1/3/16
21. Up to Date. Treatment and prognosis of Wilms tumor. Available at http://www.uptodate.com/contents/treatment-and-prognosis-of-wilms-tumor?source=search_result&search=wilms-tumor&selectedTitle=26,71150. Availability verified 1/3/16

References

22. Up to Date. Severe combined immunodeficiency (SCID): An overview. Available at http://www.uptodate.com/contents/severe-combined-immunodeficiency-scid-an-overview?source=search_result&search=SCID&selectedTitle=16,71127. Availability verified 1/3/16
23. Severe Combined Immunodeficiency. Available at <http://www.scid.net>. Availability verified 1/3/16
24. Up to Date. Severe combined immunodeficiency (SCID): Specific deficits. Available at http://www.uptodate.com/contents/severe-combined-immunodeficiency-scid-specific-deficits?source=search_result&search=SCID&selectedTitle=26,71127. Availability verified 1/3/16
25. How Kids Develop. Available at <http://www.howkidsdevelop.com/develop/DevDelay.html>. Availability verified 1/3/16
26. Piscione, P.J., Bouffet, E., Mabbott, D.J., Shams, L., Kulkarni (2014). Physical functioning in pediatric survivors of childhood posterior fossa brain tumors. *Neuro Oncology*, 16, 147-155.
27. Kennedy, E., Majnemer, A., Farmer, J.P., Barr, R.G., Platt, R.W. (2009). Motor development of infants with positional plagiocephaly. *Physical and Occupational Therapy in Pediatrics*, 29, 222-235